The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 ...
The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites. The FDA granted ...
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host ...
Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her ...
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future ...
The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry. Want more ...
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using ...
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier ...
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness. Alcon has received FDA approval for apraclonidine ophthalmic solution 0.125% (Brytly) redness relief ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results